Microport

Defibrillator Market worth $18.1 billion | MarketsandMarkets

Retrieved on: 
Monday, June 12, 2023
Aurora, Heart, Telehealth, Communication, Asahi Kasei, AED, Arrest, Boston Scientific, Public, CE marking, Survival, Quality of life, Ambulance, Defibrillation, Ease, EMS, Incidence, Patient, Microport, Machine learning, Risk, Algorithm, Emergency medical services, Vels Institute of Science, Technology & Advanced Studies, Knowledge, AI, Medical device, Music, Retail, Medtronic

Mobile and Portable Solutions: The market offers a range of portable and mobile defibrillator solutions, including wearable defibrillators and compact AEDs.

Key Points: 
  • Mobile and Portable Solutions: The market offers a range of portable and mobile defibrillator solutions, including wearable defibrillators and compact AEDs.
  • Continuous Market Growth: The global defibrillator market continues to grow, driven by the rising incidence of cardiovascular diseases, advancements in technology, and increasing focus on public access to defibrillation.
  • Defibrillator Market - Report Highlights:
    Recession Impact Analysis: The existing report includes an analysis of the impact of the recession on the market overview section.
  • Recent Market Developments: Recent developments are helpful in knowing the market trend and growth strategies adopted by players in the market.

Defibrillator Market worth $18.1 billion | MarketsandMarkets

Retrieved on: 
Monday, June 12, 2023
Aurora, Heart, Telehealth, Communication, Asahi Kasei, AED, Arrest, Boston Scientific, Public, CE marking, Survival, Quality of life, Ambulance, Defibrillation, Ease, EMS, Incidence, Patient, Microport, Machine learning, Risk, Algorithm, Emergency medical services, Vels Institute of Science, Technology & Advanced Studies, Knowledge, AI, Medical device, Music, Retail, Medtronic

Mobile and Portable Solutions: The market offers a range of portable and mobile defibrillator solutions, including wearable defibrillators and compact AEDs.

Key Points: 
  • Mobile and Portable Solutions: The market offers a range of portable and mobile defibrillator solutions, including wearable defibrillators and compact AEDs.
  • Continuous Market Growth: The global defibrillator market continues to grow, driven by the rising incidence of cardiovascular diseases, advancements in technology, and increasing focus on public access to defibrillation.
  • Defibrillator Market - Report Highlights:
    Recession Impact Analysis: The existing report includes an analysis of the impact of the recession on the market overview section.
  • Recent Market Developments: Recent developments are helpful in knowing the market trend and growth strategies adopted by players in the market.

POPE MCGLAMRY, P.C. FILES LAWSUIT AGAINST EXACTECH FOR DEFECTIVE HIP IMPLANT

Retrieved on: 
Tuesday, February 15, 2022
Bone loss, UHMWPE, Risk, Osteolysis, Biotechnology, Plaintiff, Microport, Ankle, Leadership, Knee, Pope, Stryker, Pain, Novation, DePuy, Failure, Stiffness, District court, Connexion, Medical device

ATLANTA, Feb. 15, 2022 /PRNewswire/ --On February 11, 2022, Pope McGlamry filed a federal lawsuit against orthopedic device manufacturer, Exactech, Inc.

Key Points: 
  • ATLANTA, Feb. 15, 2022 /PRNewswire/ --On February 11, 2022, Pope McGlamry filed a federal lawsuit against orthopedic device manufacturer, Exactech, Inc.
  • A hip liner is the component inserted into the artificial hip socket or cup that interfaces with the femoral head or ball.
  • On February 11, 2022, Pope McGlamry filed a federal lawsuit against orthopedic device manufacturer, Exactech, Inc.
  • The Exactech hip liner at issue is the Connexion GXL Liner, which is made of irradiated ultra-high molecular weight polyethylene (UHMWPE).

Global Defibrillator Market (2022 to 2030) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Friday, January 28, 2022
Health, Medical Devices, Cardiology, Nurse Next Door Home Healthcare Services, Awareness, Growth, Unmanned aerial vehicle, USD, Hospital, Abbott, Medtronic, External, Technology, Adoption, COVID-19, CAGR, Automated external defibrillator, Microport, CE, AED, Cobalt, Defibrillation, Pre-hospital ultrasound, IOT, Industry, Movement, ICDS, Solution, Medical device

The "Defibrillator Market Size, Share & Trends Analysis Report by Product (ICDs, External Defibrillators), by End Use (Hospital, Pre Hospital, Public Access Market, Alternate Care Market, Home Healthcare), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Defibrillator Market Size, Share & Trends Analysis Report by Product (ICDs, External Defibrillators), by End Use (Hospital, Pre Hospital, Public Access Market, Alternate Care Market, Home Healthcare), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global defibrillator market size is expected to reach USD 20.6 billion by 2030.
  • The key drivers for this market include supportive regulatory policies, rising incidences of sudden cardiac arrests, product developments, and rising awareness regarding cardiac conditions.
  • This extended the company's cardiac solutions offerings and enabled it to commercialize the products across Europe
    Chapter 3 Defibrillators Market Variables, Trends & Scope

Cardiologs' AI Improves Services for Cardiologists at Three European Medical Centers

Retrieved on: 
Thursday, September 16, 2021
Lazarus, Artificial intelligence, Acceleration, Database, AI, CEO, FDA, Technology, Deep learning, Classification, Adoption, Cardiology, Quarantine, Patient, Arrhythmia, Pressure, Software, Microport, COVID-19, Neuilly-sur-Seine, Wireless ambulatory ECG, Physician, Internet, ECG, Partnership, Telehealth, Face, Diagnosis, Time, Medical device, Medical imaging

PARIS and BOSTON, Sept. 16, 2021 /PRNewswire/ -- Cardiologs , a global leader in artificial intelligence (AI) cardiology diagnostics, is collaborating with cardiologists at three medical centers in France to strengthen their cardiology services.

Key Points: 
  • PARIS and BOSTON, Sept. 16, 2021 /PRNewswire/ -- Cardiologs , a global leader in artificial intelligence (AI) cardiology diagnostics, is collaborating with cardiologists at three medical centers in France to strengthen their cardiology services.
  • The added pressure of the Covid-19 pandemic on providers has made any solution that saves time and promotes telemedicine essential.
  • Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology.
  • Developed in partnership with leading physicians, the Cardiologs Platform empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently.

Implicity to Exhibit its Comprehensive Portfolio and Present New Scientific Data at HRS Annual Scientific Sessions

Retrieved on: 
Thursday, July 29, 2021
American brands, Companies, Medical technology, Industry economics), Cardiac electrophysiology, Biotronik, Medtronic, Microport, Microport, Boston Scientific

CAMBRIDGE, Mass., July 29, 2021 /PRNewswire/ -- Implicity , a leader in remote patient monitoring and cardiac data management solutions, today announced its newest technology will be featured at Heart Rhythm 2021 (HRS) and that the company will present scientific data at the annual Scientific Sessions.

Key Points: 
  • CAMBRIDGE, Mass., July 29, 2021 /PRNewswire/ -- Implicity , a leader in remote patient monitoring and cardiac data management solutions, today announced its newest technology will be featured at Heart Rhythm 2021 (HRS) and that the company will present scientific data at the annual Scientific Sessions.
  • Implicity's newest technology is presented in an abstract that was selected by the Scientific Committee for an e-Poster presentation.
  • The Implicity platform is medical decision aid software that collects and unifies data from all cardiac implants manufacturers (Abbott, Biotronik, Boston Scientific, Medtronic, MicroPort).
  • Implicity covers more than 40,000 patients in over 70 medical facilities across Europe and the United States.

MicroPort® Cardiac Rhythm Management Business Announces US$150 Million Series C Investment

Retrieved on: 
Tuesday, July 27, 2021
Medical technology, Cardiac electrophysiology, Branches of biology, Life sciences, Medical devices, Neuroprosthetics, Microport, Biomedical engineering, Embedded systems, Microport, Artificial cardiac pacemaker, Implantable cardioverter-defibrillator

SHANGHAI, July 27, 2021 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort") announced that MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which is MicroPort's subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million.

Key Points: 
  • SHANGHAI, July 27, 2021 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort") announced that MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which is MicroPort's subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million.
  • Hillhouse Capital Group and MicroPort will co-lead the Series C investment and will invest US$20 million and US$47 million, respectively.
  • After the completion of this transaction, MicroPort will continue to be the majority shareholder of MicroPort CRM.
  • Through its long-standing expertise in CRM, MicroPort CRM develops, manufactures and markets around the world cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure.

MicroPort Orthopedics and Medacta Agree to Settlement on Patent Claims

Retrieved on: 
Wednesday, July 14, 2021
Medicine, Medical technology, Microport, Equipment, Microport, Orthopedic surgery, Port

ARLINGTON, Tenn., July 14, 2021 /PRNewswire/ --MicroPort Orthopedics, a subsidiary of MicroPort Scientific Corporation (Stock doe: 00853.HK), and Medacta USA, Inc., a subsidiary of Medacta International SA, announced today that they have entered into an agreement to settle a suit accusing Medacta of patent infringement and tortious interference with contract.

Key Points: 
  • ARLINGTON, Tenn., July 14, 2021 /PRNewswire/ --MicroPort Orthopedics, a subsidiary of MicroPort Scientific Corporation (Stock doe: 00853.HK), and Medacta USA, Inc., a subsidiary of Medacta International SA, announced today that they have entered into an agreement to settle a suit accusing Medacta of patent infringement and tortious interference with contract.
  • The settlement also resolves MicroPort's claims against its former distributor, Advanced Surgical Devices, Inc.
    MicroPort Orthopedics leverages extensive experience in orthopedics and excellent clinical results to improve patient outcomes and drive provider satisfaction across the globe.
  • The mission of MicroPort Orthopedics is to become the trusted partner of healthcare professionals who share a belief that hip and knee replacements of the past are not good enough for the patient today.
  • With a focus on innovation combined with demonstrated capability to deliver the resources of an industry leader, MicroPort Orthopedics is helping patients worldwide achieve full function faster each and every day.

Implicity Inc. Signs U.S. Distribution Agreement with MicroPort CRM USA

Retrieved on: 
Thursday, May 27, 2021
Medical technology, Medicine, Equipment, Microport, Microport, Medical equipment, CRM, Zimmer Biomet Robotics, Port

"We are thrilled to collaborate with MicroPort CRM.

Key Points: 
  • "We are thrilled to collaborate with MicroPort CRM.
  • Implicity is a digital MedTech created in 2016 with a global presence and a strong leadership position in Europe.
  • Furthermore, Implicity carries out R&D on AI-based algorithms aiming at improving patient care and serving the future of preventive medicine.
  • MicroPort CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), and a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK ), with world headquarters in Clamart, near Paris, France.

MicroPort CRM Launches MicroPort Academy CRM, an Education Website Dedicated to Healthcare Professionals and Designed by Experts in Cardiac Pacing

Retrieved on: 
Tuesday, February 16, 2021
Education, Health, Medical devices, Practice Management, Continuing, Cardiology, Training, Medicine, Medical technology, Branches of biology, Cardiac electrophysiology, Microport, Microport, Artificial cardiac pacemaker, Electrocardiography, Port, CRM

MicroPort CRM, a subsidiary of MicroPort Scientific Corporation (Stock code: 00853.HK), a pioneering company in the field of Cardiac Rhythm Management, has launched an online education website, MicroPort Academy CRM.

Key Points: 
  • MicroPort CRM, a subsidiary of MicroPort Scientific Corporation (Stock code: 00853.HK), a pioneering company in the field of Cardiac Rhythm Management, has launched an online education website, MicroPort Academy CRM.
  • The website is dedicated to Healthcare Professionals who want to enhance their knowledge about cardiac pacing therapy and the functionality of MicroPort CRM products.
  • MicroPort Academy CRM provides personalized and interactive training plans, ranging from diagnosis of ECG tracings to techniques of pacemaker implantation, programming simulation and troubleshooting.
  • I have no doubt that MicroPort Academy CRM brings a unique experience for cardiac pacing online training.